Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 9255151.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Experience of scintigraphic detection of bone lesion and active bone marrow involvement of multiple myeloma, especially with sestamibi and FDG-PET scans is in evolution. We report a case of intense sestamibi uptake in bone marrow correlating with the extent of the disease, while FDG-PET scans showed activity only in areas of active disease progression associated with pain. Technetium-99m-sestamibi appears to indicate the extent of the disease, while [18F]FDG-PET scans show sites of active tumor proliferation and may be useful in directing local therapy such as radiation.
Medical subject headings
- Deoxyglucose
- Fluorine Radioisotopes
- Multiple Myeloma
- Radiopharmaceuticals
- Technetium Tc 99m Sestamibi
- Tomography, Emission-Computed